BCL-2
|
Forward,
|
5′-CGACTTTGCAGAGATGTCCA-3′
|
|
Reverse,
|
5′-ATGCCGGTTCAGGTACTCAG-3′
|
VEGF
|
Forward,
|
5′-GCCCTGAGTCAAGAGGACAG-3′
|
|
Reverse,
|
5′-GAGGAGGAGGAGCCATTACC-3′
|
IGF1
|
Forward,
|
5′-GCTGAAGCCGTTCATTTAGC-3′
|
|
Reverse,
|
5′-CCACCCAGTTGCTATTGCTT-3′
|
PCNA
|
Forward,
|
5′- GACCTCGCTCCCCTTACAGT -3′
|
|
Reverse,
|
5′- TCCAGCACCTTCTTCAGGAT -3′
|
SDF-1α
|
Forward,
|
5′- AGCCAGTCAGCCTGAGCTAC-3′
|
|
Reverse,
|
5′- GGCACAGTTTGGAGTGTTGA-3′
|
HIF-1α
|
Forward,
|
5′-CTAGGGATGCAGCACGATCT–3
|
|
Reverse,
|
5′-AGATGGGAGCTCACGTTGTG–3′
|
AKT 1
|
Forward,
|
5′-CCTCAAGAACGATGGCACCT-3′
|
|
Reverse,
|
5′-CAGGCAGCGGATGATAAAGG-3′
|
β-Actin
|
Forward,
|
5′- GCTGTGTTGTCCCTGTATGC-3′
|
|
Reverse, |
5′- GAGCGCGTAACCCTCATAGA-3′ |